Trial Profile
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms LeoDOR
- 27 Aug 2023 Results assessing efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute HF published in the European Journal of Heart Failure
- 12 Oct 2022 Status changed from recruiting to completed.
- 25 Aug 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.